J
John L. Johnson
Researcher at Case Western Reserve University
Publications - 203
Citations - 9340
John L. Johnson is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 52, co-authored 201 publications receiving 8445 citations. Previous affiliations of John L. Johnson include Makerere University & Universidade Federal do Espírito Santo.
Papers
More filters
Journal ArticleDOI
A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus
Christopher C. Whalen,John L. Johnson,Alphonse Okwera,David L. Hom,R. Huebner,Peter Mugyenyi,Roy D. Mugerwa,Jerrold J. Ellner +7 more
TL;DR: A six-month course of isoniazid confers short-term protection against tuberculosis among PPD-positive, HIV-infected adults and multidrug regimens with isoniaZid and rifampin taken for three months also reduce the risk of tuberculosis.
Journal ArticleDOI
Depressed T-Cell Interferon-γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy
Christina S. Hirsch,Zahra Toossi,Catherine Othieno,John L. Johnson,S. K. Schwander,Steven S. Robertson,Robert S. Wallis,K. Edmonds,Alphonse Okwera,Roy D. Mugerwa,Pierre Peters,Jerrold J. Ellner +11 more
TL;DR: The data indicate that the immunosuppression of TB is not only immediate and apparently dependent (at least in part) on Immunosuppressive cytokines early during the course of Mycobacterium TB infection but is also long lasting, presumably relating to a primary abnormality in T-cell function.
Journal ArticleDOI
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
William J. Burman,Stefan V. Goldberg,John L. Johnson,Grace Muzanye,Melissa Engle,Ann Mosher,Shurjeel Choudhri,Charles L. Daley,Sonal S. Munsiff,Zhen Zhao,Andrew Vernon,Richard E. Chaisson +11 more
TL;DR: The addition of moxifloxacin to isoniazid, rifampin, and pyrazinamide did not affect 2-mo sputum culture status but did show increased activity at earlier time points.
Journal ArticleDOI
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman,John L. Johnson,Stefan V. Goldberg,Grace Muzanye,Nesri Padayatchi,Lorna Bozeman,Charles M. Heilig,John Bernardo,Shurjeel Choudhri,Jacques H. Grosset,Elizabeth Guy,Elizabeth Guy,Priya Guyadeen,Maria Corazon Leus,Gina Maltas,Dick Menzies,Eric L. Nuermberger,Margarita E. Villarino,Andrew Vernon,Richard E. Chaisson +19 more
TL;DR: Substitution of moxifloxacin for isoniazid resulted in a small but statistically nonsignificant increase in Week-8 culture negativity.
Journal ArticleDOI
A study of the safety immunology virology and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.
Robert S. Wallis,Peter Kyambadde,John L. Johnson,Libby Horter,Rodney Kittle,Monika Pohle,Constance Ducar,Monica Millard,Harriet Mayanja-Kizza,Christopher C. Whalen,Alphonse Okwera +10 more
TL;DR: Etanercept can be safely administered during the initial treatment of pulmonary tuberculosis, and trends towards superior responses to tuberculosis treatment were evident in etanercept-treated subjects in body mass, performance score, number of involved lung zones, cavitary closure, and time to sputum culture conversion.